Akari Therapeutics (AKTX) Cash from Investing Activities (2014 - 2016)
Akari Therapeutics (AKTX) posted quarterly Cash from Investing Activities of -$46.1 million for Q2 2016, down 109507.37% on a QoQ basis from -$42083.0 in Q1 2016.
Akari Therapeutics (AKTX) Cash from Investing Activities (2014 - 2016) Analysis & Trends
Akari Therapeutics (AKTX) has reported Cash from Investing Activities for 3 consecutive years, with -$46.1 million the latest figure, recorded in Q2 2016.
- Quarterly Cash from Investing Activities changed N/A year-over-year to -$46.1 million in Q2 2016, while the trailing twelve-month figure through Jun 2016 was -$44.8 million (down 31632.64% YoY) and the FY2024 annual result came in at $382000.0, changed N/A from the prior year.
- Cash from Investing Activities slipped to -$46.1 million in Q2 2016 per AKTX's latest filing, from -$42083.0 in the prior quarter.
- Over the last five years, Cash from Investing Activities for AKTX reached as high as $1.4 million in Q3 2015 and fell as low as -$46.1 million in Q2 2016.
- A 3-year average of -$7.5 million and a median of -$30431.0 in 2015 frame the typical range for Cash from Investing Activities.
- The largest YoY upside for Cash from Investing Activities was 893.36% in 2015 against a maximum downside of 893.36% in 2015.
- Year by year, Cash from Investing Activities stood at $142000.0 in 2014, then sank by 113.22% to -$18779.0 in 2015, then plunged by 245525.8% to -$46.1 million in 2016.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$46.1 million, -$42083.0, and -$18779.0 for Q2 2016, Q1 2016, and Q4 2015 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,831.58 Bn | 66,831.30 Bn | - | - |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - | - |
| 3 | Akari Therapeutics | 976.78 Bn | 976.78 Bn | - | - |
| 4 | BeOne Medicines | 471.48 Bn | 466.69 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.78 Bn | 114.53 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.87 Bn | 61.12 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.54 Bn | 34.53 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Revolution Medicines | 37.49 Bn | 37.49 Bn | - | 172.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2016 | -46.13 Mn |
| Jun 30, 2016 | -46.13 Mn |
| Mar 31, 2016 | -42,083.00 |
| Mar 31, 2016 | -42,083.00 |
| Dec 31, 2015 | -18,779.00 |
| Dec 31, 2015 | -18,779.00 |
| Sep 30, 2015 | 1.41 Mn |
| Sep 30, 2015 | 1.41 Mn |
| Sep 30, 2014 | 142,000.00 |
| Sep 30, 2014 | 142,000.00 |
| Jun 30, 2014 | -142,000.00 |
| Jun 30, 2014 | -142,000.00 |